GLPwatch
Trulicity vs Xultophy
Drug comparison
Last updated 2026-05-28 15:46 UTCTrulicity (dulaglutide by Eli Lilly) and Xultophy (liraglutide by Novo Nordisk) are both injectable medications for type 2 diabetes. Trulicity is also approved to reduce cardiovascular risk, while Xultophy is not. Both are given as weekly shots under the skin, but Trulicity is a single ingredient, whereas Xultophy combines liraglutide with insulin degludec.
AI summary of the sources below.
| Trulicity | Xultophy | |
|---|---|---|
| Active ingredient | dulaglutide | liraglutide |
| Manufacturer | eli-lilly | novo-nordisk |
| Route | subcutaneous injection | subcutaneous injection |
| FDA-approved for | type 2 diabetes, cardiovascular risk reduction | type 2 diabetes |
| Label updated | 2023-08-05 | 2025-10-14 |